^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Follicular Lymphoma
    Drug:abexinostat (CG-781) (HDAC inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Xynomic Pharmaceuticals Press Release
    Title:

    XYNOMIC PHARMA RECEIVES FAST-TRACK DESIGNATION FROM THE US FDA FOR ABEXINOSTAT AS 4L THERAPY TREATING FOLLICULAR LYMPHOMA

    Published date:
    09/23/2019
    Excerpt:
    Xynomic Pharmaceuticals...announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast-Track designation to Xynomic’s lead drug candidate abexinostat, for use as a single agent, as a fourth-line treatment of relapsed or refractory follicular lymphoma (“FL”).